FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 343:1666-1672 December 7, 2000 Number 23 Next

	Full Text PDF Editorial by Schafer, D. F. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Covalent attachment of a 40-kd branched-chain polyethylene glycol moiety to interferon alfa-2a results in a compound (peginterferon alfa-2a) that has sustained absorption, a slower rate of clearance, and a longer half-life than unmodified interferon alfa-2a. We compared the clinical effects of a regimen of peginterferon alfa-2a with those of a regimen of interferon alfa-2a in the initial treatment of patients with chronic hepatitis C.

Methods We randomly assigned 531 patients with chronic hepatitis C to receive either 180 µg of peginterferon alfa-2a subcutaneously once per week for 48 weeks (267 patients) or 6 million units of interferon alfa-2a subcutaneously three times per week for 12 weeks, followed by 3 million units three times per week for 36 weeks (264 patients). All the patients were assessed at week 72 for a sustained virologic response, defined as an undetectable level of hepatitis C virus RNA (<100 copies per milliliter).

Results In the peginterferon group, 223 of the 267 patients completed treatment and 206 completed follow-up. In the interferon group, 161 of the 264 patients completed treatment and 154 completed follow-up. In an intention-to-treat analysis in which patients who missed the examination at the end of treatment or follow-up were considered not to have had a response at that point, peginterferon alfa-2a was associated with a higher rate of virologic response than was interferon alfa-2a at week 48 (69 percent vs. 28 percent, P=0.001) and at week 72 (39 percent vs. 19 percent, P=0.001). Sustained normalization of serum alanine aminotransferase concentrations at week 72 was also more common in the peginterferon group than in the interferon group (45 percent vs. 25 percent, P=0.001). The two groups were similar with respect to the frequency and severity of adverse events, which were typical of those associated with interferon alfa.

Conclusions In patients with chronic hepatitis C, a regimen of peginterferon alfa-2a given once weekly is more effective than a regimen of interferon alfa-2a given three times weekly.

Source Information

From the Klinikum der Johann Wolfgang Goethe Universität, Frankfurt, Germany (S.Z.); Mount Sinai Hospital, Toronto (S.V.F.); Medizinische Universitätsklinik, Freiburg, Germany (J. Rasenack); Toronto Western Hospital, Toronto (E.J.H.); National Taiwan University Hospital, Taipei, Taiwan (M.-Y.L.); Middlemore Hospital, Auckland, New Zealand (E.G.); King's College Hospital, London (J.O.); Universitätsinstitut für Klinische Pharmakologie, Bern, Switzerland (J. Reichen); General Universitario, Valencia, Spain (M.D.); and Hoffmann–LaRoche, Nutley, N.J. (A.L., J.H., M.J.B.).

Address reprint requests to Dr. Zeuzem at Medizinische Klinik II, Zentrum der Inneren Medizin, Klinikum der Johann Wolfgang Goethe Universität, Theodor-Stern-Kai 7, D-60590 Frankfurt am Main, Germany, or at zeuzem{at}em.uni-frankfurt.de.

Full Text of this Article

This article has been cited by other articles:

• Scarsi, K. K., Darin, K. M. (2009). Chronic Hepatitis B Infection: Principles of Therapy. Journal of Pharmacy Practice 22: 359-387 [Abstract]  
• Liu, C-H, Liang, C-C, Liu, C-J, Tsai, H-B, Hung, P-H, Hsu, S-J, Chen, S-I, Lin, J-W, Lai, M-Y, Chen, J-H, Chen, P-J, Chen, D-S, Kao, J-H (2009). Pegylated interferon {alpha}-2a plus low-dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy. Gut 58: 314-316 [Full Text]  
• Franchini, M., Mengoli, C., Veneri, D., Mazzi, R., Lippi, G., Cruciani, M. (2008). Treatment of chronic hepatitis C in haemophilic patients with interferon and ribavirin: a meta-analysis. J Antimicrob Chemother 61: 1191-1200 [Abstract] [Full Text]  
• Liu, C-H, Liang, C-C, Lin, J-W, Chen, S-I, Tsai, H-B, Chang, C-S, Hung, P-H, Kao, J-H, Liu, C-J, Lai, M-Y, Chen, J-H, Chen, P-J, Kao, J-H, Chen, D-S (2008). Pegylated interferon {alpha}-2a versus standard interferon {alpha}-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut 57: 525-530 [Abstract] [Full Text]  
• Murray, K. F., Rodrigue, J. R., Gonzalez-Peralta, R. P., Shepherd, J., Barton, B. A., Robuck, P. R., Schwarz, K. B., for the PEDS-C Clinical Research Network, (2007). Design of the PEDS-C trial: pegylated interferon +/- ribavirin for children with chronic hepatitis C viral infection. Clin Trials 4: 661-673 [Abstract]  
• Vansteelandt, S., Rotnitzky, A., Robins, J. (2007). Estimation of Regression Models for the Mean of Repeated Outcomes Under Nonignorable Nonmonotone Nonresponse. Biometrika 94: 841-860 [Abstract]  
• Deval, J., Powdrill, M. H., D'Abramo, C. M., Cellai, L., Gotte, M. (2007). Pyrophosphorolytic Excision of Nonobligate Chain Terminators by Hepatitis C Virus NS5B Polymerase. Antimicrob. Agents Chemother. 51: 2920-2928 [Abstract] [Full Text]  
• Ticehurst, J. R., Hamzeh, F. M., Thomas, D. L. (2007). Factors Affecting Serum Concentrations of Hepatitis C Virus (HCV) RNA in HCV Genotype 1-Infected Patients with Chronic Hepatitis. J. Clin. Microbiol. 45: 2426-2433 [Abstract] [Full Text]  
• Donlin, M. J., Cannon, N. A., Yao, E., Li, J., Wahed, A., Taylor, M. W., Belle, S. H., Di Bisceglie, A. M., Aurora, R., Tavis, J. E., for the Virahep-C Study Group, (2007). Pretreatment Sequence Diversity Differences in the Full-Length Hepatitis C Virus Open Reading Frame Correlate with Early Response to Therapy. J. Virol. 81: 8211-8224 [Abstract] [Full Text]  
• Byrnes, A. A., Li, D.-Y., Park, K., Thompson, D., Mocilnikar, C., Mohan, P., Molleston, J. P., Narkewicz, M., Zhou, H., Wolf, S. F., Schwarz, K. B., Karp, C. L. (2007). Modulation of the IL-12/IFN-{gamma} axis by IFN-{alpha} therapy for hepatitis C. J. Leukoc. Biol. 81: 825-834 [Abstract] [Full Text]  
• Butt, A. A, Justice, A. C, Skanderson, M., Rigsby, M. O, Good, C. B, Kwoh, C K. (2007). Rate and predictors of treatment prescription for hepatitis C. Gut 56: 385-389 [Abstract] [Full Text]  
• Manns, M P, Wedemeyer, H, Cornberg, M (2006). Treating viral hepatitis C: efficacy, side effects, and complications.. Gut 55: 1350-1359 [Full Text]  
• Buckton, A. J., Ngui, S.-L., Arnold, C., Boast, K., Kovacs, J., Klapper, P. E., Patel, B., Ibrahim, I., Rangarajan, S., Ramsay, M. E., Teo, C.-G. (2006). Multitypic hepatitis C virus infection identified by real-time nucleotide sequencing of minority genotypes.. J. Clin. Microbiol. 44: 2779-2784 [Abstract] [Full Text]  
• van der Eijk, A. A., Vrolijk, J. M., Haagmans, B. L. (2006). Antibodies neutralizing peginterferon alfa during retreatment of hepatitis C.. NEJM 354: 1323-1324 [Full Text]  
• Dummer, R., Garbe, C., Thompson, J. A., Eggermont, A. M., Yoo, K., Maier, T., Bergstrom, B. (2006). Randomized Dose-Escalation Study Evaluating Peginterferon Alfa-2a in Patients With Metastatic Malignant Melanoma. JCO 24: 1188-1194 [Abstract] [Full Text]  
• Wong, T., Lee, S. S. (2006). Hepatitis C: a review for primary care physicians. CMAJ 174: 649-659 [Abstract] [Full Text]  
• Hughes, C. A, Shafran, S. D (2006). Chronic Hepatitis C Virus Management: 2000-2005 Update. The Annals of Pharmacotherapy 40: 74-82 [Abstract] [Full Text]  
• Kim, Y.-C., Russell, W. K., Ranjith-Kumar, C. T., Thomson, M., Russell, D. H., Kao, C. C. (2005). Functional Analysis of RNA Binding by the Hepatitis C Virus RNA-dependent RNA Polymerase. J. Biol. Chem. 280: 38011-38019 [Abstract] [Full Text]  
• Ajariyakhajorn, C., Mammen, M. P. Jr., Endy, T. P., Gettayacamin, M., Nisalak, A., Nimmannitya, S., Libraty, D. H. (2005). Randomized, Placebo-Controlled Trial of Nonpegylated and Pegylated Forms of Recombinant Human Alpha Interferon 2a for Suppression of Dengue Virus Viremia in Rhesus Monkeys. Antimicrob. Agents Chemother. 49: 4508-4514 [Abstract] [Full Text]  
• Francois, C., Bernard, I., Castelain, S., Charleston, B., Fray, M. D., Capiod, J.-C., Duverlie, G. (2005). Quantification of Different Human Alpha Interferon Subtypes and Pegylated Interferon Activities by Measuring MxA Promoter Activation. Antimicrob. Agents Chemother. 49: 3770-3775 [Abstract] [Full Text]  
• Talpaz, M., Rakhit, A., Rittweger, K., O'Brien, S., Cortes, J., Fettner, S., Hooftman, L., Kantarjian, H. (2005). Phase I Evaluation of a 40-kDa Branched-Chain Long-Acting Pegylated IFN-{alpha}-2a With and Without Cytarabine in Patients with Chronic Myelogenous Leukemia. Clin. Cancer Res. 11: 6247-6255 [Abstract] [Full Text]  
• Mitchell, B. (2005). Review of the treatment of hepatitis C: where are we now?. British Journal of Infection Control 6: 32-34 [Abstract]  
• Hourfar, M. K., Michelsen, U., Schmidt, M., Berger, A., Seifried, E., Roth, W. K. (2005). High-Throughput Purification of Viral RNA Based on Novel Aqueous Chemistry for Nucleic Acid Isolation. Clin. Chem. 51: 1217-1222 [Abstract] [Full Text]  
• Lau, G. K., Piratvisuth, T., Luo, K. X., Marcellin, P., Thongsawat, S., Cooksley, G., Gane, E., Fried, M. W., Chow, W. C., Paik, S. W., Chang, W. Y., Berg, T., Flisiak, R., McCloud, P., Pluck, N., the Peginterferon Alfa-2a HBeAg-Positive Chronic H, (2005). Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B. NEJM 352: 2682-2695 [Abstract] [Full Text]  
• Teta, D., Luscher, B. L., Gonvers, J.-J., Francioli, P., Phan, O., Burnier, M. (2005). Pegylated interferon for the treatment of hepatitis C virus in haemodialysis patients. Nephrol Dial Transplant 20: 991-993 [Full Text]  
• Grace, M. J., Lee, S., Bradshaw, S., Chapman, J., Spond, J., Cox, S., DeLorenzo, M., Brassard, D., Wylie, D., Cannon-Carlson, S., Cullen, C., Indelicato, S., Voloch, M., Bordens, R. (2005). Site of Pegylation and Polyethylene Glycol Molecule Size Attenuate Interferon-{alpha} Antiviral and Antiproliferative Activities through the JAK/STAT Signaling Pathway. J. Biol. Chem. 280: 6327-6336 [Abstract] [Full Text]  
• Vallisa, D., Bernuzzi, P., Arcaini, L., Sacchi, S., Callea, V., Marasca, R., Lazzaro, A., Trabacchi, E., Anselmi, E., Arcari, A. L., Moroni, C., Berte, R., Lazzarino, M., Cavanna, L. (2005). Role of Anti-Hepatitis C Virus (HCV) Treatment in HCV-Related, Low-Grade, B-Cell, Non-Hodgkin's Lymphoma: A Multicenter Italian Experience. JCO 23: 468-473 [Abstract] [Full Text]  
• Carrat, F., Bani-Sadr, F., Pol, S., Rosenthal, E., Lunel-Fabiani, F., Benzekri, A., Morand, P., Goujard, C., Pialoux, G., Piroth, L., Salmon-Ceron, D., Degott, C., Cacoub, P., Perronne, C., for the ANRS HCO2 RIBAVIC Study Team, (2004). Pegylated Interferon Alfa-2b vs Standard Interferon Alfa-2b, Plus Ribavirin, for Chronic Hepatitis C in HIV-Infected Patients: A Randomized Controlled Trial. JAMA 292: 2839-2848 [Abstract] [Full Text]  
• Manns, M. P., Wedemeyer, H. (2004). Treatment of Hepatitis C in HIV-Infected Patients: Significant Progress But Not the Final Step. JAMA 292: 2909-2913 [Full Text]  
• Howe, A. Y. M., Bloom, J., Baldick, C. J., Benetatos, C. A., Cheng, H., Christensen, J. S., Chunduru, S. K., Coburn, G. A., Feld, B., Gopalsamy, A., Gorczyca, W. P., Herrmann, S., Johann, S., Jiang, X., Kimberland, M. L., Krisnamurthy, G., Olson, M., Orlowski, M., Swanberg, S., Thompson, I., Thorn, M., Del Vecchio, A., Young, D. C., van Zeijl, M., Ellingboe, J. W., Upeslacis, J., Collett, M., Mansour, T. S., O'Connell, J. F. (2004). Novel Nonnucleoside Inhibitor of Hepatitis C Virus RNA-Dependent RNA Polymerase. Antimicrob. Agents Chemother. 48: 4813-4821 [Abstract] [Full Text]  
• Li, Y., Zhang, T., Ho, C., Orange, J. S., Douglas, S. D., Ho, W.-Z. (2004). Natural killer cells inhibit hepatitis C virus expression. J. Leukoc. Biol. 76: 1171-1179 [Abstract] [Full Text]  
• Elazar, M., Liu, P., Rice, C. M., Glenn, J. S. (2004). An N-Terminal Amphipathic Helix in Hepatitis C Virus (HCV) NS4B Mediates Membrane Association, Correct Localization of Replication Complex Proteins, and HCV RNA Replication. J. Virol. 78: 11393-11400 [Abstract] [Full Text]  
• Teo, M., Hayes, P. (2004). Management of hepatitis C. Br Med Bull 70: 51-69 [Abstract] [Full Text]  
• Pimstone, N. R., Pimstone, D., Saicheur, T., Powell, J., Yu, A. S. (2004). "Wait-and-See": An Alternative Approach to Managing Acute Hepatitis C with High-Dose Interferon-{alpha} Monotherapy. ANN INTERN MED 141: W-91-W-92 [Full Text]  
• Marcellin, P., Lau, G. K.K., Bonino, F., Farci, P., Hadziyannis, S., Jin, R., Lu, Z.-M., Piratvisuth, T., Germanidis, G., Yurdaydin, C., Diago, M., Gurel, S., Lai, M.-Y., Button, P., Pluck, N., the Peginterferon Alfa-2a HBeAg-Negative Chronic H, (2004). Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B. NEJM 351: 1206-1217 [Abstract] [Full Text]  
• Matthews, J. D., Bini, E. J. (2004). Epidemiology, Diagnosis, and Treatment of Chronic Hepatitis C. Journal of Pharmacy Practice 17: 229-238 [Abstract]  
• Hakamada, T., Funatsuki, K., Morita, H., Ugajin, T., Nakamura, I., Ishiko, H., Matsuzaki, Y., Tanaka, N., Imawari, M. (2004). Identification of novel hepatitis C virus-specific cytotoxic T lymphocyte epitopes by ELISpot assay using peptides with human leukocyte antigen-A*2402-binding motifs. J. Gen. Virol. 85: 1521-1531 [Abstract] [Full Text]  
• Benvegnu, L, Gios, M, Boccato, S, Alberti, A (2004). Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 53: 744-749 [Abstract] [Full Text]  
• Fargion, S., Fracanzani, A. L., Valenti, L. (2004). Treatment choices for people infected with HCV. J Antimicrob Chemother 53: 708-712 [Abstract] [Full Text]  
• Lee, K. J., Choi, J., Ou, J.-h., Lai, M. M. C. (2004). The C-Terminal Transmembrane Domain of Hepatitis C Virus (HCV) RNA Polymerase Is Essential for HCV Replication In Vivo. J. Virol. 78: 3797-3802 [Abstract] [Full Text]  
• Chou, R., Clark, E. C., Helfand, M. (2004). Screening for Hepatitis C Virus Infection: A Review of the Evidence for the U.S. Preventive Services Task Force. ANN INTERN MED 140: 465-479 [Abstract] [Full Text]  
• Hadziyannis, S. J., Sette, H. Jr., Morgan, T. R., Balan, V., Diago, M., Marcellin, P., Ramadori, G., Bodenheimer, H. Jr., Bernstein, D., Rizzetto, M., Zeuzem, S., Pockros, P. J., Lin, A., Ackrill, A. M., for the PEGASYS International Study Group*, (2004). Peginterferon-{alpha}2a and Ribavirin Combination Therapy in Chronic Hepatitis C: A Randomized Study of Treatment Duration and Ribavirin Dose. ANN INTERN MED 140: 346-355 [Abstract] [Full Text]  
• Zeuzem, S. (2004). Heterogeneous Virologic Response Rates to Interferon-Based Therapy in Patients with Chronic Hepatitis C: Who Responds Less Well?. ANN INTERN MED 140: 370-381 [Abstract] [Full Text]  
• Sackett, D. L (2004). Superiority trials, non-inferiority trials, and prisoners of the 2-sided null hypothesis. Evid. Based Med. 9: 38-39 [Full Text]  
• Yoshida, H, Tateishi, R, Arakawa, Y, Sata, M, Fujiyama, S, Nishiguchi, S, Ishibashi, H, Yamada, G, Yokosuka, O, Shiratori, Y, Omata, M (2004). Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut 53: 425-430 [Abstract] [Full Text]  
• Adrain, A. L., Ramberan, H., Weaver, G. J. (2004). Evaluation of Common Liver Problems. J. Am. Podiatr. Med. Assoc. 94: 149-156 [Abstract] [Full Text]  
• Rocca, L. G., Yawn, B. P., Wollan, P., Kim, W. R. (2004). Management of Patients With Hepatitis C in a Community Population: Diagnosis, Discussions, and Decisions to Treat. Ann Fam Med 2: 116-124 [Abstract] [Full Text]  
• Elbeik, T., Surtihadi, J., Destree, M., Gorlin, J., Holodniy, M., Jortani, S. A., Kuramoto, K., Ng, V., Valdes, R. Jr., Valsamakis, A., Terrault, N. A. (2004). Multicenter Evaluation of the Performance Characteristics of the Bayer VERSANT HCV RNA 3.0 Assay (bDNA). J. Clin. Microbiol. 42: 563-569 [Abstract] [Full Text]  
• Moore, M. M., Elpern, D. J., Carter, D. J. (2004). Severe, Generalized Nummular Eczema Secondary to Interferon Alfa-2b Plus Ribavirin Combination Therapy in a Patient With Chronic Hepatitis C Virus Infection. Arch Dermatol 140: 215-217 [Abstract] [Full Text]  
• Blanchard, E., Hourioux, C., Brand, D., Ait-Goughoulte, M., Moreau, A., Trassard, S., Sizaret, P.-Y., Dubois, F., Roingeard, P. (2003). Hepatitis C Virus-Like Particle Budding: Role of the Core Protein and Importance of Its Asp111. J. Virol. 77: 10131-10138 [Abstract] [Full Text]  
• Gaudy, C., Moreau, A., Veillon, P., Temoin, S., Lunel, F., Goudeau, A. (2003). Significance of Pretreatment Analysis of Hepatitis C Virus Genotype 1b Hypervariable Region 1 Sequences To Predict Antiviral Outcome. J. Clin. Microbiol. 41: 3615-3622 [Abstract] [Full Text]  
• Ramos-Casals, M., Trejo, O., Garcia-Carrasco, M., Font, J. (2003). Therapeutic management of extrahepatic manifestations in patients with chronic hepatitis C virus infection. Rheumatology (Oxford) 42: 818-828 [Full Text]  
• Elazar, M., Cheong, K. H., Liu, P., Greenberg, H. B., Rice, C. M., Glenn, J. S. (2003). Amphipathic Helix-Dependent Localization of NS5A Mediates Hepatitis C Virus RNA Replication. J. Virol. 77: 6055-6061 [Abstract] [Full Text]  
• Dimitrova, M., Imbert, I., Kieny, M. P., Schuster, C. (2003). Protein-Protein Interactions between Hepatitis C Virus Nonstructural Proteins. J. Virol. 77: 5401-5414 [Abstract] [Full Text]  
• Rossi, S J, Wright, T L (2003). New developments in the treatment of hepatitis C. Gut 52: 756-757 [Full Text]  
• Prieto, J, Herraiz, M, Sangro, B, Qian, C, Mazzolini, G, Melero, I, Ruiz, J (2003). The promise of gene therapy in gastrointestinal and liver diseases. Gut 52: ii49-54 [Abstract] [Full Text]  
• Carroll, S. S., Tomassini, J. E., Bosserman, M., Getty, K., Stahlhut, M. W., Eldrup, A. B., Bhat, B., Hall, D., Simcoe, A. L., LaFemina, R., Rutkowski, C. A., Wolanski, B., Yang, Z., Migliaccio, G., De Francesco, R., Kuo, L. C., MacCoss, M., Olsen, D. B. (2003). Inhibition of Hepatitis C Virus RNA Replication by 2'-Modified Nucleoside Analogs. J. Biol. Chem. 278: 11979-11984 [Abstract] [Full Text]  
• Lee, S. S., Abdo, A. A. (2003). Predicting antiviral treatment response in chronic hepatitis C: how accurate and how soon?. J Antimicrob Chemother 51: 487-491 [Full Text]  
• Allen, S. A., Spaulding, A. C., Osei, A. M., Taylor, L. E., Cabral, A. M., Rich, J. D. (2003). Treatment of Chronic Hepatitis C in a State Correctional Facility. ANN INTERN MED 138: 187-190 [Abstract] [Full Text]  
• Sulkowski, M. S., Thomas, D. L. (2003). Hepatitis C in the HIV-Infected Person. ANN INTERN MED 138: 197-207 [Abstract] [Full Text]  
• Randall, G., Grakoui, A., Rice, C. M. (2003). Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs. Proc. Natl. Acad. Sci. USA 100: 235-240 [Abstract] [Full Text]  
• Dinwiddie, S. H., Shicker, L., Newman, T. (2003). Prevalence of Hepatitis C Among Psychiatric Patients in the Public Sector. Am. J. Psychiatry 160: 172-174 [Abstract] [Full Text]  
• Boyce, S H, Stevenson, J, Jamieson, I S, Campbell, S (2003). Impact of a newly opened prison on an accident and emergency department. Emerg. Med. J. 20: 48-51 [Abstract] [Full Text]  
• Kuehne, F. C., Bethe, U., Freedberg, K., Goldie, S. J. (2002). Treatment for Hepatitis C Virus in Human Immunodeficiency Virus-Infected Patients: Clinical Benefits and Cost-effectiveness. Arch Intern Med 162: 2545-2556 [Abstract] [Full Text]  
• Kessler, H. H., Clarici, A. M. K., Stelzl, E., Muhlbauer, G., Daghofer, E., Santner, B. I., Marth, E., Stauber, R. E. (2002). Fully Automated Detection of Hepatitis C Virus RNA in Serum and Whole-Blood Samples. CVI 9: 1385-1388 [Abstract] [Full Text]  
• Motzer, R. J., Rakhit, A., Thompson, J., Gurney, H., Selby, P., Figlin, R., Negrier, S., Ernst, S., Siebels, M., Ginsberg, M., Rittweger, K., Hooftman, L. (2002). Phase II trial of branched peginterferon-{alpha} 2a (40 kDa) for patients with advanced renal cell carcinoma. Ann Oncol 13: 1799-1805 [Abstract] [Full Text]  
• Salomon, J. A., Weinstein, M. C., Hammitt, J. K., Goldie, S. J. (2002). Empirically Calibrated Model of Hepatitis C Virus Infection in the United States. Am J Epidemiol 156: 761-773 [Abstract] [Full Text]  
• Sarrazin, C., Herrmann, E., Bruch, K., Zeuzem, S. (2002). Hepatitis C Virus Nonstructural 5A Protein and Interferon Resistance: a New Model for Testing the Reliability of Mutational Analyses. J. Virol. 76: 11079-11090 [Abstract] [Full Text]  
• Mohsen, A H, Easterbrook, P, Taylor, C B, Norris, S (2002). Hepatitis C and HIV-1 coinfection. Gut 51: 601-608 [Abstract] [Full Text]  
• Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Goncales, F. L. Jr., Haussinger, D., Diago, M., Carosi, G., Dhumeaux, D., Craxi, A., Lin, A., Hoffman, J., Yu, J. (2002). Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection. NEJM 347: 975-982 [Abstract] [Full Text]  
• Heathcote, J (2002). Weighty issues in hepatitis C. Gut 51: 7-8 [Full Text]  
• Reilly, J., Bini, E. J. (2002). Frontiers in Gastroenterology. Journal of Pharmacy Practice 15: 241-249 [Abstract]  
• Herrine, S. K. (2002). Approach to the Patient with Chronic Hepatitis C Virus Infection. ANN INTERN MED 136: 747-757 [Abstract] [Full Text]  
• Schroter, M., Zollner, B., Schafer, P., Reimer, A., Muller, M., Laufs, R., Feucht, H.-H. (2002). Epidemiological Dynamics of Hepatitis C Virus among 747 German Individuals: New Subtypes on the Advance. J. Clin. Microbiol. 40: 1866-1868 [Abstract] [Full Text]  
• Beld, M., Sentjens, R., Rebers, S., Weegink, C., Weel, J., Sol, C., Boom, R. (2002). Performance of the New Bayer VERSANT HCV RNA 3.0 Assay for Quantitation of Hepatitis C Virus RNA in Plasma and Serum: Conversion to International Units and Comparison with the Roche COBAS Amplicor HCV Monitor, Version 2.0, Assay. J. Clin. Microbiol. 40: 788-793 [Abstract] [Full Text]  
• Falck-Ytter, Y., Kale, H., Mullen, K. D., Sarbah, S. A., Sorescu, L., McCullough, A. J. (2002). Surprisingly Small Effect of Antiviral Treatment in Patients with Hepatitis C. ANN INTERN MED 136: 288-292 [Abstract] [Full Text]  
• Smith, N P, Pozniak, A L (2002). The changing face of HIV. Imaging 14: 1-7 [Abstract] [Full Text]  
• Davis, G. L (2001). Treatment of chronic hepatitis C. BMJ 323: 1141-1142 [Full Text]  
• Kjaergard, L. L, Krogsgaard, K., Gluud, C. (2001). Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials. BMJ 323: 1151-1155 [Abstract] [Full Text]  
• Hoofnagle, J. H. (2001). Therapy for Acute Hepatitis C. NEJM 345: 1495-1497 [Full Text]  
• Talpaz, M., O'Brien, S., Rose, E., Gupta, S., Shan, J., Cortes, J., Giles, F. J., Faderl, S., Kantarjian, H. M. (2001). Phase 1 study of polyethylene glycol formulation of interferon {alpha}-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 98: 1708-1713 [Abstract] [Full Text]  
• Sarrazin, C., Hendricks, D. A., Sedarati, F., Zeuzem, S. (2001). Assessment, by Transcription-Mediated Amplification, of Virologic Response in Patients with Chronic Hepatitis C Virus Treated with Peginterferon {alpha}-2a. J. Clin. Microbiol. 39: 2850-2855 [Abstract] [Full Text]  
• Edlin, B. R., Seal, K. H., Lorvick, J., Kral, A. H., Ciccarone, D. H., Moore, L. D., Lo, B. (2001). Is It Justifiable to Withhold Treatment for Hepatitis C from Illicit-Drug Users?. NEJM 345: 211-214 [Full Text]  
• Davis, G. L., Rodrigue, J. R. (2001). Treatment of Chronic Hepatitis C in Active Drug Users. NEJM 345: 215-217 [Full Text]  
• Lauer, G. M., Walker, B. D. (2001). Hepatitis C Virus Infection. NEJM 345: 41-52 [Full Text]  
• (2001). Peginterferon Alfa-2a for Patients with Chronic Hepatitis C. JWatch Gastroenterology 2001: 9-9 [Full Text]  
• Koff, R. S. (2001). Nonresponse to Interferon in Chronic Hepatitis C: Re-treatment Redux. JAMA 285: 212-214 [Full Text]  
• (2000). Peginterferon Alpha-2a: Improved Therapy for Chronic Hepatitis C, Including Cirrhosis. JWatch Infect. Diseases 2000: 1-1 [Full Text]  
• (2000). Peginterferon for Chronic Hepatitis C. JWatch General 2000: 2-2 [Full Text]  
• Heathcote, E. J., Shiffman, M. L., Cooksley, W. G. E., Dusheiko, G. M., Lee, S. S., Balart, L., Reindollar, R., Reddy, R. K., Wright, T. L., Lin, A., Hoffman, J., De Pamphilis, J. (2000). Peginterferon Alfa-2a in Patients with Chronic Hepatitis C and Cirrhosis. NEJM 343: 1673-1680 [Abstract] [Full Text]  
• Schafer, D. F., Sorrell, M. F. (2000). Conquering Hepatitis C, Step by Step. NEJM 343: 1723-1724 [Full Text]